• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
water filter
WATER FILTER FOR WATER PURIFIER
DUST BAG
Small dust filter
HUMIDIFIER FILTER
Oil fume adsorption filter

Samsung Bioepis gets nod for sale of biosimilar drug in Europe

firstwordpharmaMarch 06, 2019

Tag: Samsung Bioepis , NOD , biosimilar drug

  • Samsung Bioepis has won European approval of a 420-mg dosage of Ontruzant, a biosimilar of Roche's Herceptin, The Korea Herald reported Tuesday.

  • The drugmaker previously gained clearance for the 150-mg dosage in 2017.

  • "There is demand for both 150 mg and 420 mg products in Europe," a company official remarked, adding "we expect to provide more treatment opportunities for patients by expanding our product portfolio."

Register as Visitor to CPhI China 2019!

Previous:Johnson & Johnson's Spravato garners FDA approval for treatment-resistant depression

Next:Novo Nordisk Pharma Ltd. partners with Health2Sync in Japan, bringing digital diabetes management to healthcare providers and patients

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Samsung Bioepis gets nod for sale of biosimilar drug in Europe | Pharmasources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

IMINODIBENZYL(494-19-9)2,2'-IMINODIBENZYL

IMINODIBENZYL(494-19-9)2,2'-IMINODIBENZYL
Chenodeoxycholic acid

Chenodeoxycholic acid
Ganoderic acid D

Ganoderic acid D
4-AMINODIBENZOFURAN

4-AMINODIBENZOFURAN
4,4'-Iminodianiline

4,4'-Iminodianiline
Iminodibenzylcarbonyl chloride

Iminodibenzylcarbonyl chloride
Triterpene Reishi(Ganoderma lucidum) Mushroom Extract,Triterpene 10%

Triterpene Reishi(Ganoderma lucidum) Mushroom Extract,Triterpene 10%
Iminodibenzyl carbonyl chlorid

Iminodibenzyl carbonyl chlorid
Ganoderma Lucidum Extract

Ganoderma Lucidum Extract
23S-hydroxyl-11,15-dioxo-ganoderic acid DM

23S-hydroxyl-11,15-dioxo-ganoderic acid DM

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service